The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated•Originally published 12 April 2026•Updated 14 April 2026•

1 min read

Robeco Institutional Asset Management Adjusts Portfolio with Focus on Tech and Biotech

Satya Nadella above an Xbox Game Pass sign showing a price drop from $16.99 to $6.99. Game covers and silhouetted people below.

Key Facts

1Robeco increased its stake in Regeneron Pharmaceuticals by 116.6%, bringing the total value to over $202 million.

2The firm boosted its investment in Cadence Design Systems by 19.5%, valued at $213.5 million.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include new institutional entries from Burney Co. and expansions by PGGM, contrasted by a significant reduction from Sumitomo Mitsui and insider selling activity at Regeneron.

Regeneron Pharmaceuticals (REGN) is seeing mixed institutional activity, highlighted by Robeco Institutional Asset Management increasing its stake by 116.6% to a value of $202 million. New entry Burney Co. acquired 3,487 shares valued at $2.7 million, while other firms like Osaic Holdings and PGGM Investments also expanded their positions. Conversely, Sumitomo Mitsui Trust Group reduced its holding by 7.2%, selling 22,258 shares, alongside insider selling from Director Huda Y. Zoghbi and SVP Jason Pitofsky totaling 3,774 shares. Beyond biotech, Robeco bolstered its investment in Cadence Design Systems by 19.5% and increased its stake in Adobe, while cutting exposure to Intercontinental Exchange (ICE) by 26.5%. These portfolio adjustments reflect a nuanced institutional sentiment toward the healthcare and technology sectors amid evolving market conditions.